

Supplementary Materials:

Table S1. Year of receipt of first-line palliative systemic therapy.

<i>Year 1st-Line Palliative Systemic Therapy Received</i>	<i>Number of Patients</i>
2006	2
2007	3
2008	2
2009	4
2010	5
2011	5
2012	3
2013	10
2014	10
2015	8
2016	9
2017	6
2018	12
2019	7
2020	7
2021	1

Table S2. Fourth-line palliative systemic therapy received by patients with advanced biliary tract cancer and progression through third-line palliative systemic therapy documented prior to death.

	<i>Number of Patients (n = 66)</i>
5-FU/platinum	5 (7.6%)
5-FU/irinotecan	6 (9.1%)
Gem/platinum	4 (6.1%)
Gem	3 (4.5%)
RXC004 plus Nivolumab	1 (1.5%)

5-FU = 5-fluorouracil. Gem = gemcitabine.

Table S3. First- and second-line palliative systemic therapy received by patients with advanced biliary tract cancer defined as 'other' in Table 1.

	<i>Number of Patients</i>
First-line therapy	
Gem	2
Cis/Gem plus durvalumab/placebo	2
Cis/Gem plus cediranib	1
EOX	1
5-FU/irinotecan	1
Second-line therapy	
Capecitabine	6
Gem/capecitabine	5
5-FU	2
Gem	1
Durvalumab plus tremelimumab	1
Regorafenib plus avelumab	1
Capecitabine/platinum	1

Gem = gemcitabine. 5-FU = 5-fluorouracil. EOX = epirubicin, oxaliplatin, capecitabine.